Home > Resources > Whitepapers > Unleash Your Biologic

Unleash Your Biologic

March 28, 2018

For biopharmaceutical quantification, it is important that these often highly concentrated biologic drugs can be measured with high accuracy in a dilution-free and batch-wise manner. While most analysis methods don’t cover all of these aspects and tend to suffer from some inherent drawbacks such as labor-intensity or incompatibility with certain buffers, Unchained Labs’ Lunatic platform tackles all these issues with confidence.

Spotlight

Leap Therapeutics

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.

OTHER WHITEPAPERS

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.